TrialInvestigational new drugs2020
Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Ling Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this paperpooled ittrialcites it